System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Javier Martinez-Trufero is an expert in Oncology at Hospital Universitario Miguel Servet (Spain). As of October 2026, ScienceLeadR ranks Javier Martinez-Trufero in the top 1% of experts worldwide for Chondrosarcoma and Sarcoma. Javier Martinez-Trufero has authored 156 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 8 of them ongoing. SLR score: 904 (community average: 125). How the SLR is computed.

LeadR Profile

Javier Martinez-Trufero Hospital Universitario Miguel Servet Spain
904 ScienceLeadR Reputation 904

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Endocrinology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Hospital Universitario Miguel Servet

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 156

Citations

Citations: 3 329 1st author: 13 Last author: 13 Unique author: 1

Main journals

J Clin Oncol 48
Ann Oncol 17
Clin Transl Oncol 12
Cancer 4
Oncologist 4

Best Journals

J Clin Oncol 17
Ann Oncol 6
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe.
PMID 42704687 — neoplasms, income, sarcoma, diagnosis		Oncologist20260
Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis.
PMID 42542734 — cells, genes, t-lymphocytes, regulatory, myeloid-derived suppressor cells, disease-free survival, progression-free survival, biomarkers, sarcoma, cell line, therapeutics, tissues, prognosis		Ther Adv Med Oncol20260
Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012-2022) in Ibero-American countries.
PMID 42516945 — registries, sarcoma, therapeutics, tissues		Lancet Reg Health Am20260
MDM4 Amplification in Liposarcoma: A Rare Finding or an Underrecognized Pathway?
PMID 42478652 — liposarcoma, pathology, surgical		Int J Surg Pathol20260
Expert opinion document on the management of desmoid tumours in adult patients in Spain.
PMID 42435159 — fibromatosis, aggressive, neoplasms, algorithms, therapeutics		Clin Transl Oncol20260

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 2 9
Phase 1/Phase 2 6
Phase 3 6
Phase 2/Phase 3 3
Phase 4 2
Phase 1 1

By status:

Recruiting 12
Completed 9
Unknown 5
Active not recruiting 1

By type:

Interventional 27

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 2
multicentric5to9 4
multicentricup10 21

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
A study to test long term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine
2024-514177-21-00 — safety, therapeutics		Phase 2Recruiting2024
An Open label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumor Aggressive Fibromatosis (DT AF)
2024-515215-21-00 — fibromatosis, aggressive, ovary, neoplasms, female		Phase 4Recruiting2025
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first line treatment of recurrent and or metastatic squamous cell carcinoma of the head and neck
2025-522996-27-00 — cells, carcinoma, squamous cell, squamous cell carcinoma of head and neck, therapeutics, carcinoma, head, neck		Phase 3Recruiting2026
Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT)
2024-519261-21-00 — cells, desmoplastic small round cell tumor, neoplasms, therapeutics, irinotecan		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS